Floatz logo

Docetaxel

Adenocarcinoma of the Prostate

Instituto do Cancer do Estado de São PauloSmall moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

96 Active assets in the Adenocarcinoma of the Prostate cohort.

Asset / SponsorPhaseRating
Degarelix
Canadian Cancer Trials Group
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2BB
NILUTAMIDE
SWOG Cancer Research Network
Phase 3BB
PREDNISONE TABLETS
Mayo Clinic
Phase 3BB
Casodex
OHSU Knight Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →